# Protocol Review and Monitoring System

> **NIH NIH P30** · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · 2020 · $6,764

## Abstract

PROTOCOL REVIEW & MONITORING SYSTEM (PRMS) 
ABSTRACT 
The Protocol Review and Monitoring System (PRMS) at the University of New Mexico Cancer Center (UNMCC) 
is an essential component of the clinical research performed at the UNMCC. The PRMS provides a fully 
integrated clinical research management system for cancer clinical trials at UNMCC and community studies 
throughout New Mexico, which includes medical and scientific review and a single statewide cancer IRB 
submission process with cooperating legal agreements between participating institutions. Since 2002, the New 
Mexico Cancer Care Alliance (NMCCA) created by Cheryl L. Willman, MD, Director and CEO of the UNMCC, 
along with two community-based physicians and two New Mexico community health care systems, has 
successfully functioned as a statewide cancer clinical trials organization and clinical research network which has 
grown to include 5 community-based healthcare systems and the majority of oncologists statewide. The NMCCA 
is physically housed in the UNMCC and its oversight and management is under the auspices of the UNMCC 
Clinical Research Office. The PRMS supports this unique clinical research network that was developed in the 
State of New Mexico, and is scientifically driven by UNMCC. PRMS represents a key structure at UNMCC to 
prioritize and implement clinical research based on our scientific missions, developed through our Research 
Programs and activated at UNMCC as well through the NMCCA and the UNMCC consortium partners. With the 
unique structure to deliver clinical research to the entire State of New Mexico through the UNMCC's statewide 
cancer clinical trials network, NMCCA, the UNMCC PRMS is the State's PRMS. The PRMS is led by Teresa 
Rutledge, MD, Associate Professor, Department of Obstetrics and Gynecology, Division of Gynecologic 
Oncology. In 2014, Dr. Rutledge was awarded the NCI Cancer Clinical Investigator Team Leadership Award. 
During the previous funding period (2010 to 6/1/2014), the PRMS reviewed and prioritized 338 clinical research 
studies; of the trials reviewed and prioritized 46% were NCI studies, 15% were investigator initiated and 38% 
were industry sponsored. In 2013, a total of 79 protocols were submitted to the Clinical Working Groups for 
review; the Working Groups declined 20 of these studies and 5 were withdrawn. There were 67 protocols 
submitted for scientific review to the PRMC in calendar year 2013; 3 were declined by the PRMC. Of the studies 
closed from January 2013 to June 30, 2014, 9 were investigator-initiated studies that were completed, 4 were 
closed due to low accrual rates, 1 was closed due to toxicity, and 2 were closed due to lack of efficacy.

## Key facts

- **NIH application ID:** 10230661
- **Project number:** 3P30CA118100-15S9
- **Recipient organization:** UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
- **Principal Investigator:** CHERYL LYNN WILLMAN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $6,764
- **Award type:** 3
- **Project period:** 2005-09-26 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10230661

## Citation

> US National Institutes of Health, RePORTER application 10230661, Protocol Review and Monitoring System (3P30CA118100-15S9). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10230661. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
